Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial

BACKGROUND: No standard maintenance treatment has been obtained to prolong the response duration of soft tissue sarcoma (STS) after first-line chemotherapy. In this study, we aimed to evaluate the efficacy and safety of anlotinib as a maintenance treatment after chemotherapy in STS. METHODS: In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Bushu, Pan, Qiuzhong, Pan, Hua, Li, Haomiao, Li, Xianan, Chen, Jing, Pang, Danmei, Zhang, Baoqing, Weng, Desheng, Peng, Ruiqing, Fang, Meiyu, Zhang, Xing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520347/
https://www.ncbi.nlm.nih.gov/pubmed/37767191
http://dx.doi.org/10.1016/j.eclinm.2023.102240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520347/
https://www.ncbi.nlm.nih.gov/pubmed/37767191
http://dx.doi.org/10.1016/j.eclinm.2023.102240

Ejemplares similares